Drug name - Synribo

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6987103 TEVA PHARMS INTL Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents Oct, 2026

(4 years from now)

Drugs and Companies using OMACETAXINE MEPESUCCINATE ingredient

Treatment: Treatment of patients with tyrosine kinase inhibitor (tki) resistant or intolerant chronic myeloid/myelogenous leukemia (cml)


More Information on Dosage
Strength Dosage Availability

availability in other generic markets.

Click on the highlighted region to filter.